Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

BACKGROUND: Rivaroxaban is established for the treatment and secondary prevention of venous thromboembolism, but whether it is useful in patients with antiphospholipid syndrome is uncertain. METHODS: This randomised, controlled, open-label, phase 2/3, non-inferiority trial, done in two UK hospitals,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Hannah, Hunt, Beverley J, Efthymiou, Maria, Arachchillage, Deepa R J, Mackie, Ian J, Clawson, Simon, Sylvestre, Yvonne, Machin, Samuel J, Bertolaccini, Maria L, Ruiz-Castellano, Maria, Muirhead, Nicola, Doré, Caroline J, Khamashta, Munther, Isenberg, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010562/
https://www.ncbi.nlm.nih.gov/pubmed/27570089
http://dx.doi.org/10.1016/S2352-3026(16)30079-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010562/
https://www.ncbi.nlm.nih.gov/pubmed/27570089
http://dx.doi.org/10.1016/S2352-3026(16)30079-5

Ejemplares similares